

1

2

3

4 **The expression of cancer stem cells and its effects on the propensity for**
5 **recurrence and metastasis in bladder cancer: a systematic review**

6

7

8 Agus Rizal Ardy Hariandy Hamid^{1*}, Yasmina Zahra Syadza¹, Oliver Emmanuel Yausep¹, Roberto
9 Bagaskara Indy Christanto¹, Bayu Hernawan Rahmat Muharia¹, Chaidir Arif Mochtar¹

10

11

12 ¹ Department of Urology, Faculty of Medicine Universitas Indonesia – Dr. Cipto
13 Mangunkusumo Hospital, Jakarta

14

15

16 * Corresponding author

17 Email: rizalhamid.urology@gmail.com (RZ)

18

19 Running title: Cancer stem cells as bladder cancer recurrence and metastasis marker

20

21

22 **Abstract**

23 Bladder cancer is one of the most frequent cancers of the urinary tract, associated
24 with high recurrence rates and metastasis. Cancer stem cells (CSCs) are a subpopulation of
25 cancer cells characterized by high self-renewal and differentiation capacities, resulting in
26 increased cancer recurrence, larger tumor size, higher rates of metastasis, higher resistance
27 to treatment, and overall poorer prognosis. This study aimed to evaluate the role of CSCs
28 as a prognostic tool to predict the risks of metastasis and recurrence in bladder cancer. A
29 literature search was conducted across seven databases from January 2000 to February
30 2022 for clinical studies investigating the use of CSCs to determine the prognosis of
31 bladder cancer. The following keywords were used: (“Bladder Cancer” OR “Transitional
32 Cell Carcinoma” OR “Urothelial Carcinoma”) AND (“Stem Cell” OR “Stem Gene”) AND
33 (“Metastasis” OR “Recurrence”). A total of 12 studies were deemed eligible for inclusion.
34 SOX2, IGF1R, SOX4, ALDH1, CD44, Cripto-1, OCT4, ARRB1, ARRB2, p-TFCP2L1,
35 CDK1, DCLK1, and NANOG, which were all identified as CSC markers, have been
36 implicated in the recurrence and metastasis of tumor in bladder cancer, which played a role
37 as prognostic factor of bladder cancer. Given the pluripotent and highly proliferative
38 properties of CSCs. CSCs may play a role in the complex biological behavior of bladder
39 cancer, including, but not limited to, its high rates of recurrence, metastasis, and resistance
40 to treatment. The detection of cancer stem cell markers offers a promising approach in
41 determining the prognosis of bladder cancer. Further studies in this area are thus warranted
42 and may contribute significantly to the overall management of bladder cancer.

43 **Keywords:** Cancer stem cells; Bladder cancer; Recurrency of bladder cancer; Metastasis
44 of bladder cancer; Prognosis factor of bladder cancer

45 **Introduction**

46 Bladder cancer (BCa) is the most common neoplasm of the urinary tract and the
47 fifth most prevalent malignancy worldwide. High-grade bladder tumors are more likely to
48 progress to muscle-invasive disease and have a higher tendency to undergo distant
49 metastasis. In contrast, low-grade tumors rarely invade the bladder musculature and
50 metastasize. [1-3] However, both non-muscle-invasive bladder cancer (NMIBC) and
51 muscle-invasive bladder cancer (MIBC) have a high propensity of recurrence, with a 50–
52 90% probability of recurrence within five years. [4] In addition, metastatic BCa is
53 considered incurable. [5] Several established risk factors related to higher risks of disease
54 progression include tumor grade, tumor size, and tumor multiplicity; however, these risk
55 factors are insufficient to address important prognostic indicators such as recurrence rates
56 and progression in individual cases. [6, 7] Thus, there is an urgent need to identify novel,
57 more reliable prognostic factors for BCa.

58 Cancer stem cells (CSCs), also known as tumor-initiating cells, are a subpopulation
59 of undifferentiated yet tumorigenic cells within a neoplasm that are capable of tumor
60 initiation, self-renewal, and proliferation, which are thought to be responsible for tumor
61 progression, relapse, metastasis, and heterogeneity. [8, 9] CSC expressions have been
62 identified in multiple human solid tumors, including breast, prostate, ovarian, and lung
63 cancers, and are significantly associated with metastasis-free survival and other clinical
64 outcomes. [10] Bladder cancer stem cells (BCSCs) were first identified using markers for
65 isolation of normal stem cells in 2009. [11] Since then, BCSCs have emerged as a growing
66 field of research, with genome-wide screening methods and platforms for establishing
67 therapeutic targets for tumor-initiating cell populations. [12] A more profound

68 understanding of BCSCs and their effects on BCa may provide helpful prognostic tools
69 and novel therapeutic targets. However, the clinical impacts of BCSC expressions and
70 functions have not been fully elucidated yet. Hence, this systematic review aims to evaluate
71 all available evidence regarding BCSCs and their roles in predicting the risks of metastasis
72 and recurrence in BCa.

73

74 **Materials and methods**

75 **Objectives**

76 This article aims to provide a systematic review of primary clinical studies to
77 identify the BCSCs markers, which have played a role as prognostic factors in BCa
78 patients.

79

80 **Study design**

81 This systematic review was created in accordance with the guidelines for Preferred
82 Reporting Items for Systematic Reviews and Meta-analysis (PRISMA). [13] We
83 determined inclusion criteria, data synthesis methods, and outcomes in advanced in a
84 protocol registered with PROSPERO (CRD42021268964).

85

86 **Search strategy**

87 A literature search for clinical studies evaluating CSCs as a prognostic indicator in
88 BCa published from January 2000 to February 2022 was conducted from several databases,
89 such as Pubmed, Scopus, EMBASE, Science Direct, Proquest, CINAHL, and The
90 Cochrane Library. The search following key terms used based on the PICO were applied
91 to identify eligible publications: (“Bladder Cancer” OR “Transitional Cell Carcinoma” OR
92 “Urothelial Carcinoma”) AND (“Stem Cell” OR “Stem Gene”) AND (“Metastasis” OR
93 “Recurrence”). Initially, study titles and abstracts were screened. Subsequently, full text
94 analysis of selected articles was done based on pre-set eligibility criteria. In addition, the
95 reference lists of included studies were further evaluated to identify potential studies.
96 Literature screening and analysis were undertaken separately by two independent
97 researchers.

98

99 **Eligibility criteria**

100 Our inclusion criteria were as follows: (1) studies evaluating the impacts of BCSC
101 expressions on BCa recurrence and/or metastasis; (2) prospective or retrospective cohort
102 studies or case control studies; and (3) publications written in English. Animal and *in vitro*
103 studies were excluded.

104

105 **Outcomes**

106 The primary outcomes of this systematic review are the effect of BCSC expressions
107 toward recurrence and metastasis in BCa. In addition, survival analyses from several
108 studies were also presented.

109

110 **Data extraction**

111 Two authors independently run the systematic search and screened the articles.
112 From all eligible studies, data were also extracted independently, and any disagreement
113 were resolved through discussion among all authors. Data recorded from each study were
114 as follow: author's name, year of publication, study design, number of study's participant,
115 intervention given to the participant, method used for gene expression analysis, outcomes
116 (recurrence-free survival and metastasis-free), and mean or median year follow-up. The
117 effect measures used were the hazard ratios and their respective 95% confidence intervals
118 for both univariate and multivariate analyses.

119

120 **Quality assessment**

121 The qualities of the selected studies were assessed using the Newcastle-Ottawa
122 Scale (NOS). Using this tool, selected studies were assessed based on three aspects: the
123 selection of the study groups; the comparability of the groups; and the ascertainment of
124 either the outcome of interest for case-control or cohort studies, respectively. Good quality
125 studies have 3 to 4 stars in the selection component, 1 to 2 stars in the comparability
126 component, and 3 stars in the outcome component. Fair quality studies have 2 stars in the

127 selection component, 1 to 2 stars in the comparability component, and 2 to 3 stars in the
128 outcome component. Poor quality studies have 0 to 1 star in the selection component, 0
129 star in the comparability component, and 0 to 1 star in the outcome component. The quality
130 assessment showed in Table 1.

131 **Table 1. Risk of bias assessment using Newcastle Ottawa Score (NOS)**

No	Study	Selection (Max *)				Comparability (Max **)	Outcome (Max *)			Score
		Representativeness of exposed cohort	Selection of exposed cohort	Ascertainment of exposure	No outcome of interest at start	Comparability of cohorts based on design or analysis	Assessment of outcome	Was followed up long enough for outcomes to occur	Adequacy of follow up of cohorts	
1	Ruan et al., 2012 [6]	*	*	*	*	*	*	*	*	8
2	Keymoosi et al., 2014 [13]	*	*	*	*	*	*	*	*	8

3	Wei et al., 2014 [14]	*	*	*	*	*	*	*	*	8
4	Senol et al., 2015 [15]	*	*	*	*	*	*	*	*	8
5	Sedaghat et al., 2016 [2]	*	*	*	*	*	*	N/A	*	7
6	Siddiqui et al., 2019 [16]	*	*	*	*	*	*	*	*	8
7	Chiu et al., 2020 [17]	*	N/A	*	*	N/A	*	N/A	*	5
8	Shen et al., 2015 [1]	*	*	*	*	**	*	*	*	9

9	Xu et al., 2015 [18]	*	*	*	*	*	*	*	*	8
10	Heo et al., 2019 [19]	*	*	*	*	*	*	N/A	*	7
11	Shaifei et al., 2019 [20]	*	*	*	*	*	*	N/A	*	7
12	Kallifatidis et al., 2019 [21]	*	*	*	*	*	*	*	-	7

133 **Result**

134 **Study selection**

135 The flow diagram in the form of PRISMA diagram for study selection is shown in
136 (Figure 1). We included 12 clinical studies evaluating effects of BCSCs expression on
137 tumor recurrence and/or metastasis, consisted of cohorts and case controls studies,
138 involving at least 2230 patients (one study did not specify the sample size) with BCa and
139 68 non-tumor tissue for control in this systematic review. All the eligible studies were
140 published between 2012 and 2020.

141

142 **Study characteristics**

143 All of the studies selected were reviewed and the result were displayed on Table 1.
144 We reviewed the intervention given to the patient, gene expression analysis, and outcomes
145 which was consisted of recurrence and metastasis. Eleven out of 12 studies assessed the
146 recurrence-free survival related to the BCSCs and five studies out of 12 studies assessed
147 the metastasis associated with BCSCs. Only four studies which analyzed both tumor
148 recurrence and metastasis. Only three studies provided data about mean or median follow-
149 up time Table 2.

150

151 **Association between BCSCs expression with**

152 **clinicopathological parameters**

153 We identified several BCSCs in this review, which included SOX2, SOX4,
154 ALDH1, CD44, Nanog, Cripto-1, OCT4, CD133, β -arrestin-1 (ARRB1) and β -arrestin-2
155 (ARRB2), IGF1R, p-TFPC2L1, and CDK1. Eight out of 12 studies included performed
156 Kaplan-Meier survival analysis to compare the effect of respective BCSCs expression on
157 clinicopathological parameters. All of the gene were found to be significant prognostic
158 factors based on univariate analysis. Moreover, multivariate analysis using Cox regression
159 also showed that the majority of gene expression were independent prognostic factors; thus,
160 it may play a role as a potentially valuable marker in predicting the recurrence-free,
161 metastasis-free, or disease-free (recurrence/metastasis-free) with $P < 0.05$ Table 3.

162

163 **Table 2. Study characteristics**

Study (year)	Design	Participants	Control	Intervention	Gene Expression Analysis	Outcomes		Mean or median follow-up
						Recurrence	Metastasis	
Ruan et al., 2012 [6]	Case-control	32 BCa tissues	32 corresponding normal tissues	-	qRT-PCR IHC	High SOX2 expression significantly played a role in predicting the recurrence-free survival in T1 BCa patients	-	2 years

Keymoosi et al., 2013 [13]	Prospective Cohort	159 patients with urothelial carcinoma	-	TURBT with no prior chemotherapy or radiation therapy	IHC on TMA slides	High ALDH1 and CD44 expressions were correlated with a significantly increased rate of recurrence (P=0.013)	-	46 months
Wei et al., 2014 [14]	Prospective cohort	130 BCa patients	-	Cystectomy or Transurethral resection of the bladder tumor.	qRT-PCR IHC	High Cripto-1 was significantly associated with expression and tumor recurrence or metastasis (P=0.007)	-	Not available

Senol et al., 2015 [15]	Prospective cohort	163 cases of urothelial carcinomas of the bladder (UCB)	-	-	IHC	ALDH1 expression was significantly associated with disease recurrence (P<0.001), however, CD44 was not significantly associated (P=0.688)	-	23.60□ 16.88 months
Sedaghat et al., 2016 [2]	Retrospective cohort	140 tissues from transitional cell carcinoma samples	-	-	TMA-based IHC	OCT4 expression had no correlation with tumor recurrence (P=0.32) or CD133 (p=0.71)	-	Not available

Siddiqui et al., 2019 [16]	Prospective cohort	112 histopathologically proven BCa		Bacillus Calmette Gurein (BCG), non-BCG, radical cystectomy with and without adjuvant therapy	IHC	High CD44 and NANOG expression were significantly associated with lower tumor recurrence (P<0.001)	-	Not available
Chiu et al., 2020 [17]	Retrospective cohort	For patients with transitional cell carcinoma of the urinary bladder,	-	-	IHC staining with SOX2 antibody	High SOX2 and IGF1R expression was correlated with poor recurrence-free survival and was increased in "poorly differentiated"	-	Not available

		sample size not specified				malignant grade tumors (P=0.0187)		
Shen et al., 2015 [1]	Retrospec tive cohort	309 patients with transitional cell carcinoma of the urinary bladder	-	-	IHC	High Sox4 expression was significantly associated with higher tumor grade (more likely to recurrent). (P = 3.71E-10)	High Sox4 expression was significantly associated with invasiveness (more likely to spread to other parts of the	Not availabl e

							body). (P = 7.00E-04)	
Xu et al., 2015 [18]	Prospective Cohort	227 patients with bladder urothelial cell carcinoma (118 non-invasive and 109 invasive)	-	118 patients with non-invasive bladder carcinoma: 11 underwent radical cystectomy and 107 underwent intravesical chemotherapy after transurethral resection	IHC using ALDH1A1 antibody and secondary antibody from EnVision System	ALDH1 expression was significantly associated with tumor recurrence (P ≤ 0.05).	ALDH1 expression was significantly associated with lymph node (P = 0.008) and tumor distant metastases (P = 0.018)	52-months

				109 patients with invasive disease: 69 underwent radical cystectomy. 20 underwent partial cystectomy; and 20 underwent transurethral resection				
--	--	--	--	--	--	--	--	--

Heo J et al., 2019 [19]	Retrospective cohort	400 patients with urothelial carcinoma	-	TURBT	IHC	p-TFCP2L1 and CDK1 expression were not associated with recurrence (P=0.563)	High levels of co-expression of p-TFCP2L1 and CDK1 were associated with distant metastasis (P=0.442)	Not available
Shaifei et al., 2019 [20]	Case-control	472 bladder tumors	16 matched adjacent non-cancerous normal tissue	TURBT with no prior neoadjuvant treatment before surgery	IHC on TMA slides	DCLK1 expression was not associated with recurrence (P=0.314)	DCLK1 expression was significantly associated with distant metastasis (P=0.042)	Not available

Kallifatidis et al., 2019 [21]	Retrospective cohort	43 bladder tumors in cohort 1; 43 bladder tumors in cohort 2	20 normal bladder	Cohort 2 receiving gemcitabine + cisplatin	RT-q-PCR		ARRB1 transcript levels in bladder tumor specimens from patients who developed metastasis were 7.7-fold elevated compared to the normal bladder and 5.2-fold elevated compared to BCa specimens from patients who did not develop metastasis	Not available
--------------------------------	----------------------	--	-------------------	--	----------	--	--	---------------

164 ICH, Immunohistochemistry; NMIBC, non-muscle-invasive bladder cancer;(tissue microarray); qRT-PCR, Real-Time Quantitative

165 Reverse Transcription Polymerase Chain Reaction; TURBT, Transurethral Resection of Bladder Tumor

166 **Table 3. Univariate and multivariate analysis of recurrence and metastasis as prognostic factors in patients with bladder**
 167 **carcinoma**

Outcome	Gene expression	Study (year)	Univariate analysis		Multivariate analysis	
			HR (95% CI)	P value	HR (95% CI)	P value
Recurrence -free	SOX2	Chiu (2020)	2.467 (1.292-4.709)	0.0062	2.966 (1.451-6.064)	0.0029
		Ruan (2013)	4.2 (1.827-9.654)	0.001	3.187 (1.130-8.990)	0.029
	ALDH1	Xu (2015)	2.84 (1.19-7.14)	0.040	-	-
	CD44/Nanog	Siddiqui (2019)	32.52 (9.79-107.99)	<0.001	25.45 (6.71-96.50)	<0.001
	ALDH1	Senol (2015)	-	-	4.590 (2.042-10.319)	0.001
	CD44		-	-	0.548(0.283-1.059)	0.074
Metastasis	ARRB1	Kallifatidis (2020)	1.35 (1.06-1.71)	0.0137	1.07 (1.01-1.13)	0.015
	ARRB2		0.03 (0.35-0.003)	0.005	0.13 (0.86-0.02)	0.006

Disease-free (recurrence / metastasis)	Cripto-1	Wei (2015)	2.678 (1.280-5.605)	0.009	2.306 (1.055-5.039)	0.036
	DCLK1	Shafiei (2019)	1.642 (1.063-2.534)	0.025	1.564 (1.004-2.434)	0.048

168

169

170 **Discussion**

171 Cancer cells utilize normal stem cell self-renewal for long-term proliferation and
172 tissue-repair pathways for invasion; therefore, CSCs expression in cancer may be
173 associated with disease prognosis and treatment outcomes. [1] Association between tumor
174 biology and CSCs has been addressed in various types of cancer, including breast cancer,
175 colorectal cancer, and bladder cancer. Many studies have revealed that CSCs were
176 considered as an important factor leading to tumor recurrence and metastatic; however, its
177 exact mechanisms are still unclear and may have a different pathway one to another. [22]
178 By identifying and understanding the molecular mechanism of In recurrent and metastatic
179 BCa, numerous stem cell phenotypes, such as beta arrestins, SOX2, SOX4, transcription
180 factor CP2 like 1 (TFCP2L1), and doublecortin-like kinase 1 (DCLK1), have all been
181 identified and described.

182 Two studies reporting a significant relationship between high expression of SOX2
183 with poor recurrence-free survival also found that SOX2 was highly expressed in tumors
184 with poor pathological differentiation; thus, marking its role in BCa malignancy. SOX2
185 plays a role in promoting cell proliferation and enhancing cell survival during low-serum
186 stress. BCa cancer cells' survival and spheroid-forming capability enhancement were
187 induced by AKT phosphorylation due to IGF2/IGF1R induction, which was thought to be
188 involved in molecular mechanism of SOX2 expression leading to poor tumor prognosis.
189 Its mechanism made SOX2 a potential therapeutic target for BCa treatment. [6, 17]

190

191 CD44 was one of the most stem cells which has been widely studied and was
192 commonly expressed in BCa with a poor prognosis. Hu *et al.* [19] conducted a meta-
193 analysis about the prognostic value of CD44 expression in BCa and found that CD44
194 expression may be associated with advanced T stage, tumor grade, and lymph node
195 metastasis, but not with recurrence-free survival and overall survival of the disease.
196 ALDH1 was also commonly reported to be a significant prognostic factor in tumor
197 recurrence and metastasis. Xu *et al.* [18] and Senol *et al.* [15] further conducted univariate
198 and multivariate survival analyses and also observed a statistically significant association
199 between ALDH1 expression and recurrence-free survival ($P<0.05$). Moreover, Xu *et al.*
200 also found that ALDH1 expression was related to tumor distant metastasis. [18]

201 An inverse expression of ARRB1 and ARRB2 both significantly correlated with
202 tumor metastasis. Kallifatidis *et al.* [21] conducted univariate and multivariate analysis and
203 found that up-regulation of ARRB1 and down-regulation of ARRB2 both played a role as
204 functional biomarkers to predict metastasis ($P<0.05$). Kallifatidis *et al.* [21] reported that
205 ARRB2 negatively regulated the activation of STAT3, a transcription factor regulating the
206 self-renewal nature of BCSCs. Conversely, ARRB1 was found to positively regulate BMI-
207 1 and ARRB-1 were linked with poorer prognosis in BCa. [21] Overexpression of DCLK1
208 which was previously reported to be remarkable in cell progression and metastasis of
209 colorectal cancer, was also found to be a significant prognostic factor on BCa. Multivariate
210 Cox regression analyses conducted by Shafiei *et al.* [20] showed DCLK1 protein
211 expression was an independent prognostic factor to poor disease-specific survival in BCa
212 patients. However, the molecular mechanism of the protein expression was not yet well-
213 established. Cripto-1 or teratocarcinoma-derived growth factor-1 (TDGF-1) was found to

214 have a significant association with tumor recurrence/metastasis in BCa patients (P=0.007)
215 and also as an independent prognostic factor identified with multivariate Cox regression
216 analysis (P=0.036), which validated its role to be a valuable marker as a disease-free
217 predictor in BCa patients. [14]

218 This systematic review showed that most BCSCs expressions were significantly
219 associated with tumor recurrence and metastasis, suggesting its important role in patients'
220 prognosis. CSC-specific cell-surface markers represent potential therapeutic targets. By
221 knowing stem cell expression in BCa, therapeutic strategies could be set and implemented
222 to improve disease outcomes. However, the mechanism of each CSCs was reported to be
223 different due to its heterogeneity in the level of stem cells. Many cell-surface markers and
224 signaling pathways are distinct in quiescent cells and proliferating cells; thus,
225 microenvironmental interactions can alter stem cells' marker expression and signaling
226 pathways. [1] Therefore, a major consideration for this approach remains the specificity of
227 these markers. [2] In addition, specific CSC phenotypes appear to be correlated with
228 disease outcomes, including risks of recurrence and metastasis. [2] Based on these findings,
229 further studies regarding CSCs, especially their molecular mechanism, are warranted and
230 may have significant contribution to the overall management of BCa.

231 Our study has several limitations. The majority of studies included did not show
232 the mean or median follow-up time to determine the outcome. Each study also had different
233 patients' characteristics, tumors' profiles, and treatment plans, which may also affect the
234 recurrence and metastasis. We only presented a systematic review without further analysis;
235 thus, we only can show that many studies have shown the beneficial impact of identifying
236 BCSCs, and further studies are required.

237 Larger multicenter studies are needed to assess each factor that contributed to the
238 recurrence and metastasis of BCa. However, statistical analysis sometimes has poor
239 accuracy and is not applicable individually; thus, artificial intelligence has been further
240 developed and may answer this problem. There have been several research that stated that
241 artificial intelligence was believed to accurately predict cancer behavior, overall survival,
242 and disease recurrence on BCa. Furthermore, Artificial intelligence can provide patient-
243 tailored instruments for diagnosing and managing BCa.

244

245

246 **Conclusions**

247 The detection of cancer stem cell expression offers a promising modality in
248 predicting the prognosis of BCa. However, much is lacking in the molecular mechanisms
249 underlying these processes. Hence, future research in this area is warranted and may highly
250 contribute to the overall management of BCa.

251

252

253 **Funding**

254 This work was supported by Universitas Indonesia for funding this research through
255 PUTI Grant with contract number NKB-1533/UN2.RST/HKP.05.00/2020.

256

257

258 **COMPETING INTERESTS**

259 The authors declare that there were no competing interests.

260

261 **Author Contributions**

262 **Conceptualization:** Agus Rizal Ardy Hariandy Hamid, Chaidir Arif Mochtar

263 **Data curation:** Agus Rizal Ardy Hariandy Hamid

264 **Formal analysis:** Agus Rizal Ardy Hariandy Hamid, Yasmina Zahra Syadza

265 **Investigation:** Chaidir Arif Mochtar

266 **Methodology:** Yasmina Zahra Syadza, Oliver Emmanuel Yausep, Roberto Bagaskara Indy

267 Christanto

268 **Project administration:** Bayu Hernawan Rahmat Muharia

269 **Software:** Oliver Emmanuel Yausep, Roberto Bagaskara Indy Christanto

270 **Supervision:** Agus Rizal Ardy Hariandy Hamid, Chaidir Arif Mochtar

271 **Validation:** Agus Rizal Ardy Hariandy Hamid, Chaidir Arif Mochtar, Yasmina Zahra

272 Syadza

273 **Visualization:** Yasmina Zahra Syadza, Bayu Hernawan Rahmat Muharia

274 **Writing – Original draft:** Yasmina Zahra Syadza, Oliver Emmanuel Yausep, Roberto
275 Bagaskara Indy Christanto

276 **Writing – review & editing:** Agus Rizal Ardy Hariandy Hamid, Chaidir Arif Mochtar

277 **References**

- 278 1. Shen H, Blijlevens M, Yang N, Frangou C, Wilson KE, Xu B, et al. Sox4 expression
279 confers bladder cancer stem cell properties and predicts for poor patient outcome.
280 International Journal of Biological Sciences. 2015;11(12):1363–75.
- 281 2. Sedaghat S, Gheytauchi E, Asgari M, Roudi R, Keymoosi H, Madjd Z. Expression of
282 Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas. Applied
283 Immunohistochemistry and Molecular Morphology. 2017;25(3):196–202.
- 284 3. Tanaka T, Miyazawa K, Tsukamoto T, Kuno T, Suzuki K. Pathobiology and
285 chemoprevention of bladder cancer. Journal of Oncology. 2011;2011.
- 286 4. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, et al. Identification,
287 molecular characterization, clinical prognosis, and therapeutic targeting of human
288 bladder tumor-initiating cells. Proceedings of the National Academy of Sciences of the
289 United States of America. 2009;106(33):14016–21.
- 290 5. Hermann GG, Horn T, Steven K. The influence of the level of lamina propria invasion
291 and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell
292 bladder cancer. Journal of Urology. 1998;159(1):91–4.

- 293 6. Ruan J, Wei B, Xu Z, Yang S, Zhou Y, Yu M, et al. Predictive value of Sox2 expression
294 in transurethral resection specimens in patients with T1 bladder cancer. *Medical*
295 *Oncology*. 2013;30(1).
- 296 7. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem
297 cells. *Nature*. 2001;414(November):105–11.
- 298 8. Jordan CT, Guzman ML, Noble M. Cancer stem cells. *New England Journal of*
299 *Medicine*. 2006;355(12):1253–61.
- 300 9. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, et al. Cancer stem
301 cells in solid tumors: An overview and new approaches for their isolation and
302 characterization. *FASEB Journal*. 2013;27(1):13–24.
- 303 10. Li Y, Lin K, Yang Z, Han N, Quan X, Guo X, et al. Bladder cancer stem cells: clonal
304 origin and therapeutic perspectives. *Oncotarget*. 2017;8(39):66668–79.
- 305 11. Abugomaa A, Elbadawy M, Yamawaki H, Usui T, Sasaki K. Emerging Roles of Cancer
306 Stem Cells in Bladder Cancer Progression, Tumorigenesis, and Resistance to
307 Chemotherapy: A Potential Therapeutic Target for Bladder Cancer. *Cells*. 2020;9(1):1–
308 19.
- 309 12. Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred
310 reporting items for systematic reviews and meta-analyses: The PRISMA statement.
311 *PLoS Medicine*. 2009;6(7).
- 312 13. Keymoosi H, Gheytonchi E, Asgari M, Sharifab A, Madjd Z. ALDH1 in Combination
313 with CD44 as Putative Cancer Stem Cell Markers are Correlated with Poor Prognosis

- 314 in Urothelial Carcinoma of the Urinary Bladder. *Asian Pac J Cancr Prev*.
315 2014;15(5):2013–9.
- 316 14. Wei B, Jin W, Ruan J, Xu Z, Zhou Y, Liang J, et al. Cripto-1 expression and its
317 prognostic value in human bladder cancer patients. *Tumor Biology*. 2015 Feb
318 27;36(2):1105–13.
- 319 15. Senol S, Yildirim A, Akalin I, Uruç F, Çobanoğlu B, Yilmaz S, et al. Relation of stem
320 cell markers ALDH1 and CD44 with clinicopathological factors in urothelial
321 carcinomas of urinary bladder [Internet]. Vol. 8, *Int J Clin Exp Med*. 2015. Available
322 from: www.ijcem.com/
- 323 16. Siddiqui Z, Srivastava A, Sankhwar S, Dalela D, Singh V, Zaidi N, et al. Synergic
324 effects of cancer stem cells markers, CD44 and embryonic stem cell transcription factor
325 Nanog, on bladder cancer prognosis. *British Journal of Biomedical Science*. 2019;1–7.
- 326 17. Chiu YF, Wu CC, Kuo MH, Miao CC, Zheng MY, Chen PY, et al. Critical role of
327 SOX2–IGF2 signaling in aggressiveness of bladder cancer. *Scientific Reports*. 2020
328 Dec 1;10(1).
- 329 18. Xu N, Shao MM, Zhang HT, Jin MS, Dong Y, Ou RJ, et al. Aldehyde dehydrogenase
330 1 (ALDH1) expression is associated with a poor prognosis of bladder cancer. *Cancer*
331 *Epidemiology*. 2015 Jun 1;39(3):375–81.
- 332 19. Heo J, Noh B, Lee S, Lee H, Kim Y, Lim J, et al. Phosphorylation of TFCEP2L1 by
333 CDK1 is required for stem cell pluripotency and bladder carcinogenesis. *EMBO*
334 *Molecular Medicine*. 2020 Jan 9;12(1).

- 335 20. Shafiei S, Kalantari E, Saeednejad Zanjani L, Abolhasani M, Asadi Lari MH, Madjd
336 Z. Increased expression of DCLK1, a novel putative CSC marker, is associated with
337 tumor aggressiveness and worse disease-specific survival in patients with bladder
338 carcinomas. *Experimental and Molecular Pathology*. 2019 Jun 1;108:164–72.
- 339 21. Kallifatidis G, Smith DK, Morera DS, Gao J, Hennig MJ, Hoy JJ, et al. B-arrestins
340 regulate stem cell-like phenotype and response to chemotherapy in bladder cancer.
341 *Molecular Cancer Therapeutics*. 2019 Apr 1;18(4):801–11.
- 342 22. Kang Y, Zhu X, Wang X, Liao S, Jin M, Zhang L, et al. Identification and Validation
343 of the Prognostic Stemness Biomarkers in Bladder Cancer Bone Metastasis. *Frontiers*
344 *in Oncology*. 2021 Mar 19;11.
- 345




Figure 1